Karyopharm Therapeutics | KPTI - Ebitda


Karyopharm Therapeutics reported $-26.2M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Abbott USD 2.43B 844M Mar/2026
Amgen USD 3.86B 1.28B Mar/2026
AstraZeneca USD 5.16B 510M Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -30.2M 52.15M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novartis USD 5.41B 431M Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Takeda JPY 364.46B 214.21B Jun/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
TG Therapeutics USD 26.9M 1.21M Jun/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Xencor USD -34.63M 86.74M Jun/2026